Patents by Inventor Claire MONTPELLIER

Claire MONTPELLIER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230340030
    Abstract: Hepatitis E virus (HEV) is responsible for over 50% of acute viral hepatitis cases worldwide. The inventors have now identified the precise sequence of infectious particle-associated ORF2 capsid protein. Strikingly, their analyses revealed that in infected patients, HEV produces three forms of the ORF2 capsid protein: ORF2i, ORF2g and ORF2c. The ORF2i protein is associated with infectious particles whereas ORF2g and ORF2c proteins are massively produced glycoproteins that are not associated with infectious particles and are the major antigens present in HEV-infected patient sera. Accordingly, the ORF2i and ORF2g proteins are thus the subject matter of the present invention as well as antibodies specific for the proteins and diagnostic assays (e.g. ELISA) for the diagnosis of Hepatitis E virus infection.
    Type: Application
    Filed: March 1, 2023
    Publication date: October 26, 2023
    Inventors: Laurence COCQUEREL-DEPROY, Claire MONTPELLIER, Jean DUBUISSON, Anne GOFFARD
  • Publication number: 20210324049
    Abstract: Hepatitis E virus (HEV) is annually responsible for 20 million infections with 3.4 million symptomatic cases and 70,000 deaths mainly occurring in less developed regions of the world. HEV is a non-enveloped virus containing a linear, single-stranded, positive-sense RNA genome that contains three open reading frames (ORFs), namely, ORF1, ORF2 and ORF3. ORF2 encodes the ORF2 viral capsid protein, which is involved in particle assembly, binding to host cells and eliciting neutralizing antibodies. Recently, 3 different forms of the ORF2 capsid protein were identified: infectious/intracellular ORF2 (ORF2i), glycosylated ORF2 (ORF2g), and cleaved ORF2 (ORF2c). The ORF2i protein, for which the precise sequence has been identified, is the form that is associated with infectious particles and thus antibodies having specificity for the ORF2i protein would be suitable for the diagnosis of HEV.
    Type: Application
    Filed: July 9, 2019
    Publication date: October 21, 2021
    Inventors: Laurence COCQUEREL-DEPROY, Claire MONTPELLIER, Jean DUBUISSON
  • Publication number: 20210269510
    Abstract: Hepatitis E virus (HEV) is annually responsible for 20 million infections with 3.4 million symptomatic cases and 70,000 deaths mainly occurring in less developed regions of the world. HEV is a quasi-enveloped virus containing a linear, single-stranded, positive-sense RNA genome that contains three open reading frames (ORFs), namely, ORF1, ORF2 and ORF3. ORF2 encodes the ORF2 viral capsid protein, which is involved in particle assembly, binding to host cells and eliciting neutralizing antibodies. Recently, 3 different forms of the ORF2 capsid protein were identified: infectious/intracellular ORF2 (ORF2i), glycosylated ORF2 (ORF2g), and cleaved ORF2 (ORF2c). The ORF2i protein, for which the precise sequence has been identified, is the form that is associated with infectious particles and thus antibodies having specificity for the ORF2i protein would be suitable for the diagnosis of HEV.
    Type: Application
    Filed: July 9, 2019
    Publication date: September 2, 2021
    Inventors: Laurence COCQUEREL-DEPROY, Claire MONTPELLIER, Jean DUBUISSON
  • Publication number: 20210179669
    Abstract: Hepatitis F virus (HEV) is responsible for over 50% of acute viral hepatitis cases worldwide. The inventors have now identified the precise sequence of infectious particle-associated ORF2 capsid protein. Strikingly, their analyses revealed that in infected patients, HEV produces three forms of the ORF2 capsid protein: ORF2i, ORF2g and ORF2c. The ORF2i protein is associated with infectious particles whereas ORF2g and ORF2c proteins are massively produced glycoproteins that are not associated with infectious particles and arc the major antigens present in HEV-infected patient sera. Accordingly, the ORF2i and ORF2g proteins are thus the subject matter of the present invention as well as antibodies specific for the proteins and diagnostic assays (e.g. ELISA) for the diagnosis of Hepatitis E virus infection.
    Type: Application
    Filed: November 24, 2020
    Publication date: June 17, 2021
    Inventors: Laurence COCQUEREL-DEPROY, Claire MONTPELLIER, Jean DUBUISSON, Anne GOFFARD
  • Patent number: 10875896
    Abstract: Hepatitis E virus (HEV) is responsible for over 50% of acute viral hepatitis cases worldwide. The inventors have now identified the precise sequence of infectious particle-associated ORF2 capsid protein. Strikingly, their analyses revealed that in infected patients, HEV produces three forms of the ORF2 capsid protein: ORF2i, ORF2g and ORF2c. The ORF2i protein is associated with infectious particles whereas ORF2g and ORF2c proteins are massively produced glycoproteins that are not associated with infectious particles and are the major antigens present in HEV-infected patient sera. Accordingly, the ORF2i and ORF2g proteins are thus the subject matter of the present invention as well as antibodies specific for the proteins and diagnostic assays (e.g. ELISA) for the diagnosis of Hepatitis E virus infection.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: December 29, 2020
    Assignees: INSERM (Institut National de la Santé´et de la Recherche Médicale), Institut Pasteur de Lille, Centre National de la Recherche Scientifique (CNRS), Universitë{umlaut over ( )}de Lille, Centre Hospitalier Regional Universitaire de Lille
    Inventors: Laurence Cocquerel-Deproy, Claire Montpellier, Jean Dubuisson, Anne Goffard
  • Publication number: 20190352342
    Abstract: Hepatitis E virus (HEV) is responsible for over 50% of acute viral hepatitis cases worldwide. The inventors have now identified the precise sequence of infectious particle-associated ORF2 capsid protein. Strikingly, their analyses revealed that in infected patients, HEV produces three forms of the ORF2 capsid protein: ORF2i, ORF2g and ORF2c. The ORF2i protein is associated with infectious particles whereas ORF2g and ORF2c proteins are massively produced glycoproteins that are not associated with infectious particles and are the major antigens present in HEV-infected patient sera. Accordingly, the ORF2i and ORF2g proteins are thus the subject matter of the present invention as well as antibodies specific for the proteins and diagnostic assays (e.g. ELISA) for the diagnosis of Hepatitis E virus infection.
    Type: Application
    Filed: January 29, 2018
    Publication date: November 21, 2019
    Inventors: Laurence COCQUEREL-DEPROY, Claire MONTPELLIER, Jean DUBUISSON, Anne GOFFARD